MEDICAL

Felix Biotechnology Announces Initiation of CYPHY Phase 1/2 study at Yale for Lead Asset

Felix Biotechnology | January 08, 2021

Felix Biotechnology reported the inception of CYPHY, a Phase 1/2 examiner started single focus preliminary at Yale University for focused phage treatment YPT-01 in the therapy of constant P. aeruginosa diseases in cystic fibrosis. This twofold visually impaired, fake treatment controlled study (NCT 04684641) will evaluate the wellbeing and adequacy of YPT-01 added to standard antimicrobial treatment in 36 patients. CYPHY will likewise evaluate the capacity of YPT-01 to lessen the harmfulness and anti-infection obstruction of P. aeruginosa, improving patient results and re-empowering utilization of conventional anti-infection agents against multi-drug safe strains. The lead specialist for this investigation, Dr. Jon Koff, Associate Professor and Director of Yale's Adult Cystic Fibrosis Program, is supported by an academic grant from the Cystic Fibrosis Foundation.

"This is a fantastic opportunity to show how effective phage therapy can be when deployed in an evolutionary framework. We know that pathogens evolve resistance to any antibiotic or therapy we use, so our approach turns that to our advantage," said Dr. Paul Turner, Professor of Ecology and Evolutionary Biology, co-inventor of YPT-01, and co-founder of Felix Biotechnology. "By targeting phage to mechanisms of virulence, we ensure that if pathogens evolve resistance to phage, they lose traits that make them effective pathogens, putting them in an evolutionary Catch-22."

Spotlight

University professors and public sector scientists are regarded as highly credible sources of information on biotechnology. Hence, their role in science communication, particularly on biotechnology is critical. A survey was conducted to investigate how Filipino academics and scientists involved in crop biotechnology view science communication and their role in public awareness and understanding.

Spotlight

University professors and public sector scientists are regarded as highly credible sources of information on biotechnology. Hence, their role in science communication, particularly on biotechnology is critical. A survey was conducted to investigate how Filipino academics and scientists involved in crop biotechnology view science communication and their role in public awareness and understanding.

Related News

INDUSTRY OUTLOOK

BIOMEDICAN Enters the Astaxanthin Market Through Biosynthesis Platform to Target High-Value Compound and Disrupt the Current Technologies

BIOMEDICAN | December 03, 2020

BIOMEDICAN, a biotech organization planning patented minimal methods for developing high-value compounds at scale with proprietary yeasts, has entered the Astaxanthin market to diversify products outside of Cannabinoids. This new advancement permits BIOMEDICAN's biosynthesis platform to focus on any high-value compound and fundamentally disturb the current advances. Astaxanthin is a widely used, high-value compound known as a powerful antioxidant and anti-inflammatory. The Astaxanthin market comprises of three primary segments: fish feed, animal feed, and human utilization. Astaxanthin's worth is developing astronomically: its market was worth over $1 billion in 2019 and is projected to be worth $3.3 billion by 2027.

Read More

Ginkgo Bioworks Announces Partnership with Totient to Identify Neutralizing Antibodies Against COVID-19

Ginkgo Bioworks | September 11, 2020

Today, Ginkgo Bioworks announced a partnership with Totient, an AI-driven drug discovery company emerging from stealth, to rapidly identify neutralizing antibodies against COVID-19. Through this partnership, Totient will leverage Ginkgo's bioengineering platform to express and screen thousands of antibody candidates with the aim of identifying broadly neutralizing therapeutic antibodies against COVID-19 for further development. Totient leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. As the broader scientific community mobilizes to address the coronavirus pandemic, Totient has partnered with Ginkgo to adapt and scale its platform, which has been validated in oncology and autoimmunity, to aid in the effort to discover COVID-19 antibodies. Totient's population-scale antibody discovery platform reconstructs anti-SARS-CoV-2 antibodies from bronchoalveolar lavage fluid (BALF) samples.

Read More

RESEARCH

AlivaMab Discovery Services is Expanding the Drug Discovery Platform with the Introduction of New Antibody Engineering Department

AlivaMab | May 13, 2021

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expertise in antibody engineering includes bispecific antibodies, some of which have reached clinical trials, antibody-drug conjugates, Fc modification, in vitro display for antibody discovery and optimization, and structural modeling. “An increasing number of leading pharma and biotechs realize that ADS's pre-existing platform process adds exceptional value to their antibody drug discovery efforts. I am excited to be leading the initiative at ADS to develop new capabilities that will expand the scope and importance that we offer to our clients' drug discovery and development projects. The new Antibody Engineering Department's commitment will help to ensure that ADS delivers the best antibody drug candidates,” said Jonah Rainey, Vice President of Antibody Engineering at AlivaMab Discovery Services. “Today, we significantly expand the ADS discovery platform by adding a new pillar of antibody engineering to our existing pillars of Ablexis' AlivaMab® Mouse, the leading transgenic animal technology for antibody drug discovery, a suite of AMMPD immunization technologies to address even the most challenging targets, a broad sampling of the immune repertoire through function-first high-throughput deep sequencing, and a broad sampling of the immune repertoire through function-first high-throughput sequence analysis. “Jonah's skills and abilities complement and reinforce the ADS team's accumulated decades of experience in discovery and development. We assist our clients in delivering quality medicines to patients quicker by combining team, technology, and partnership.” About AlivaMab Discovery Services AlivaMab Discovery Services is a privately-owned biotechnology company that develops an integrated antibody therapeutic discovery platform that combines innovative technologies and deep expertise to produce superior antibody therapeutics on time. Throughout their careers, the team has completed over 200 discovery projects, yielding several antibody drug candidates in clinical trials. ADS offers a wide range of antibody therapeutic candidates with complex molecular and epitope profiles, functional and kinetic characterization, and superior developability profiles.ADS is trusted by organizations ranging from global pharmaceutical firms to virtual biotechnology companies because of its business model that relies solely on partners instead of developing an internal product pipeline.

Read More